Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib

Haematologica. 2005 Nov:90 Suppl:ECR36.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Combined Modality Therapy
  • Cytarabine / therapeutic use
  • Drug Resistance, Neoplasm
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Fusion Proteins, bcr-abl / genetics
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cell Mobilization*
  • Humans
  • Imatinib Mesylate
  • Interferons / therapeutic use
  • Lenograstim
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Leukemia, Myeloid, Chronic-Phase / drug therapy
  • Leukemia, Myeloid, Chronic-Phase / genetics
  • Leukemia, Myeloid, Chronic-Phase / surgery*
  • Male
  • Peripheral Blood Stem Cell Transplantation*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Recombinant Proteins / pharmacology
  • Remission Induction
  • Transplantation, Autologous*

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Recombinant Proteins
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Lenograstim
  • Imatinib Mesylate
  • Interferons
  • Fusion Proteins, bcr-abl